We are only able to display limited information for this firm. We display more complete information for all of the following firms:

Motley Rice LLC, which is based in Hartford, has been steadily emerging as a force in securities litigation over the last 20 years, reaching a peak in 2022 with the $809.5m settlement in a case against Twitter in which the firm acted as co-lead counsel. Since then, it has continued to build its reputation, and in 2023 it secured a $125m settlement as co-lead counsel in a securities class action against Alexion Pharmaceuticals, Inc. to resolve claims that the company boosted its sales of commercial drug Soliris with illegal and unethical sales practices. Practice head William Narwold in Hartford, Connecticut, led that case, with support from Gregg Levin, William Norton and Joshua Littlejohn, who are all based in Mount Pleasant, South Carolina. Also based in Mount Pleasant is key partner Lance Oliver, who has extensive experience in class actions, mass torts, and other complex matters. Veteran securities litigator Serena Hallowell in New York recently worked with Norton on In re Sotera Health Company Securities Litigation, a consolidated class action alleging that Sotera made false and misleading statements about its environmental controls and liability exposure.

Legal 500 Editorial commentary

Testimonials

Collated independently by Legal 500 research team.

  • 'Serena Hallowell is responsive and diligent in providing updates and discussing procedural and substantive issues in developing the case. She is respectful and mindful of my time, but makes sure to flag important issues when she deems them a high priority.'
Abbreviated data is displayed for this firm.

Key clients

  • KBC Asset Management NV
  • Universal-Investment-Gesellschaft mbH
Abbreviated data is displayed for this firm.

Work highlights

  • Sole Lead Counsel and Co-Class Counsel for Twitter shareholders and led negotiations for a $809.5 million settlement.
  • Co-Lead Counsel for Lead Plaintiffs and the Class of Alexion investors who suffered damages when Alexion’s management admitted to a “tone at the top” problem that allegedly increased sales of the Company’s only money-making drug, Soliris through illegal practices that violated federal laws, industry standards, and ethical regulations. The Court granted preliminary approval of a $125 million settlement on Sept. 19, 2023.
Abbreviated data is displayed for this firm.